Drugs / 1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecalciferol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001151 | Mar 1976 → Oct 2009 | rickets | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1,25-Dihydroxycholecalciferol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001151 ↗ |
| Known as | 1,25(OH)2D3 | “In previously treated patients maintenance vitamin D will be gradually replaced with 1,25(OH)2D3.” NCT00001151 ↗ |
| Known as | 1,25-dihydroxyvitamin D3 | “Patients diagnosed with these disorders will be evaluated and treated with high doses of another form of Vitamin D (1,25-dihydroxyvitamin D3).” NCT00001151 ↗ |
| Known as | 1,25-dihydroycholecalciferol | “Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day.” NCT00001151 ↗ |
| Route | Oral | “will be administered orally” NCT00001151 ↗ |